ADG116 + Immunotherapy for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG106, a fully human ligand-blocking agonistic anti-CD137 IgG4 mAb, is expected to enhance the activity of activated T cells. The enhanced antitumor efficacy results observed from the preclinical studies of ADG116 in combination with ADG106 or anti-PD-1 provided further support to explore such combinations in clinical settings for better patient responses.
Are You a Good Fit for This Trial?
Adults over 18 with advanced solid tumors who've exhausted standard treatments or can't access them may join this trial. They should have a life expectancy over 12 weeks, be relatively healthy (ECOG status 0-1), and have at least one measurable tumor lesion. Prior therapies must be completed at least 4 weeks before the study starts, and they shouldn't have severe previous side effects from similar drugs.Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive dose escalation of ADG116, either as monotherapy or in combination with ADG106 or anti-PD-1 antibody
Treatment
Participants receive the study medication, ADG116, in combination with ADG106 or anti-PD-1 antibody to evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ADG106
- ADG116
- Anti-PD-1 Antibody
Find a Clinic Near You
Who Is Running the Clinical Trial?
Adagene Inc
Lead Sponsor